New targeted painkillers potentially requiring fewer doses and with less side effects are being developed by a University of Queensland startup.
Qld firm hones next-generation painkillers
Australian scientists are working on new painkilling drugs that are more targeted and with fewer side effects for people living with debilitating and chronic pain.
The medicines, which target a molecule believed to affect how the human body senses pain, are being developed by University of Queensland startup Cassowary Pharmaceuticals.
Company founder and UQ biotechnology expert Trent Munro says this type of therapy reduces potential side effects and safety issues associated with current pain treatments, and requires fewer doses.
“Creating drugs with these attributes could change the lives of millions of people who suffer from chronic neuropathic pain,” Professor Munro said in a statement.